Tereos : -29% decline in EBITDA for 2024/25 and very cautious guidance for 2025/26, with leverage that could reach 5x.|IHO roadshow feedback: ContiTech monetisation could help IHO to de-lever… but earliest 2026|Emeria: Q1 2025 results reassuring despite ongoing liquidity concerns|Isabel Marant: despite a further improvement in the topline, EBITDA fell again in Q1|Tough 2025 results, withdrawal of 2026 targets, Q1 2026 revenue expected to drop by 20%, and new CFO|
Tereos : publication d’une baisse de -29% de l’EBITDA en 2024/25 et guidance très prudente pour 2025/26, avec un levier qui pourrait aller jusqu’à 5x.|IHO roadshow feedback: ContiTech monetisation could help IHO to de-lever… but earliest 2026|Emeria : un T1 2025 rassurant même si la liquidité reste critique|Isabel Marant : malgré une nouvelle amélioration de la topline, l’Ebitda est à nouveau en baisse au T1|Résultats 2025 difficiles, retrait des objectifs 2026, CA T1 2026 attendu en baisse org....
4Q'24 vs. 4Q'23 Results Sales: € 2.521 Bn (+6.6% vs. +5.6% BS(e)); EBITDA: € 449.5 M (+12.9% vs. +1.4% BS(e)); Net Profit: € 3.3 M (-98.3% vs. -73.5% BS(e)); FY2024 vs. FY2023 Results Sales: € 9.071 Bn (+0.5% vs. +0.2% BS(e)); EBITDA: € 1.435 Bn (-6.2% vs. -9.1% BS(e)); EBIT: € 725.4 M (n/a vs. n/a BS(e)); Net Profit: € 429.9 M (-27.3% vs. -19.3% BS(e));
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.